Paul Baas

List of Publications by Year
in descending order

25 papers	7,239 citations	759233 12 h-index	713466 21 g-index
25 all docs	25 docs citations	25 times ranked	10187 citing authors

#	Article	IF	Citations
1	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	13.7	5,456
2	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1276.	7.1	670
3	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. Ca-A Cancer Journal for Clinicians, 2019, 69, 402-429.	329.8	306
4	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 1569-1576.	1.1	206
5	Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respiratory Medicine,the, 2019, 7, 260-270.	10.7	190
6	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1â€“positive advanced nonâ€“small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer, 2019, 135, 188-195.	2.0	189
7	Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine, 2020, 62, 103040.	6.1	35
8	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. Translational Lung Cancer Research, 2020, 9, 1169-1179.	2.8	30
9	Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respiratory Medicine,the, 2021, 9, 585-592.	10.7	30
10	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a â€˜chemosensitiveâ€™ relapse: A single-arm phase II study (EORTC-08061). European Journal of Cancer, 2016, 54, 35-39.	2.8	17
11	Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma. Chest, 2019, 156, 754-763.	0.8	17
12	BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Molecular Cancer Therapeutics, 2021, 20, 379-388.	4.1	13
13	Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. EBioMedicine, 2021, 64, 103160.	6.1	13
14	Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses. Clinical Cancer Research, 2018, 24, 1761-1770.	7.0	12
15	Progression free survival rate at 9 and 18weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. European Journal of Cancer, 2014, 50, 2771-2782.	2.8	11
16	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2021, , .	1.1	11
17	Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. Thorax, 2022, 77, 1260-1267.	5.6	11
18	Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. Translational Lung Cancer Research, 2020, 9, 1736-1748.	2.8	9

#	Article	IF	Citations
19	Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus. Journal of Thoracic Oncology, 2018, 13, 1619-1622.	1.1	6
20	Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates. Journal of Thoracic Oncology, 2018, 13, 1577-1587.	1.1	5
21	Nose in malignant mesotheliomaâ€"Prediction of response to immune checkpoint inhibitor treatment. European Journal of Cancer, 2021, 152, 60-67.	2.8	2
22	Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study. Lung Cancer, 2019, 138, 139-140.	2.0	0
23	Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. Journal of Geriatric Oncology, 2020, 11, 529-532.	1.0	0
24	Going Beyond Results of the PEMBRO-RT Trialâ€"Reply. JAMA Oncology, 2020, 6, 162.	7.1	0
25	Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19. Lung Cancer, 2021, 161, 197-199.	2.0	0